| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53) |
| Gene ID | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Synthesized phospho-peptide around the phosphorylation site of human p53 (Phospho-Ser366) |
| Conjugate | |
| Concentration | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
tumor protein p53(TP53) Homo sapiens This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013],
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes p53 (Phospho-Ser366). It is validated for Western Blot, ELISA.
Validated Applications
| Applications | Western Blot, ELISA |
|---|---|
| WB 1 | 500-2000, ELISA 1:10000-20000 |
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
Synthesized phospho-peptide around the phosphorylation site of human p53 (Phospho-Ser366)
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Rat, Mouse |
| Immunogen | Synthesized phospho-peptide around the phosphorylation site of human p53 (Phospho-Ser366) |
| Concentration | 1 mg/mL |
| Observed Band | 53kD |
| Subcellular Location | Cytoplasm . Nucleus . Nucleus, PML body . Endoplasmic reticulum . Mitochondrion matrix . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Recruited into PML bodies together with CHEK2 (PubMed:12810724). Translocates to mitochondria upon oxidative stress (PubMed:22726440). Translocates to mitochondria in response to mitomycin C treatment (PubMed:27323408). .; [Isoform 1]: Nucleus . Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cy |
| Swiss-Prot | P04637 |
| Gene ID | 7157 |
| Storage | -20°C/1 year |
Reactivity Notes
Validated reactivity: Human, Rat, Mouse. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for p53 (Phospho-Ser366) research from ELK Biotechnology, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
